Gyre Therapeutics, Inc. GYRE Payments to Acquire Restricted Certificates of Deposit
Payments to Acquire Restricted Certificates of Deposit at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s payments to acquire restricted certificates of deposit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s payments to acquire restricted certificates of deposit?
- Gyre Therapeutics, Inc. (GYRE) reported payments to acquire restricted certificates of deposit of $12.95M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s payments to acquire restricted certificates of deposit changed year-over-year?
- Gyre Therapeutics, Inc.'s payments to acquire restricted certificates of deposit increased by 54.1% year-over-year, from $8.4M to $12.95M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s payments to acquire restricted certificates of deposit?
- Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s payments to acquire restricted certificates of deposit has grown at a 23.2% compound annual growth rate (CAGR), from $7.48M to $14.01M.
- What does payments to acquire restricted certificates of deposit mean?
- This metric represents cash outflows used to purchase certificates of deposit that are subject to withdrawal restrictions or are pledged as collateral. These assets are typically held to satisfy regulatory requirements, lease guarantees, or other contractual obligations. It provides insight into the portion of the company's liquidity that is not readily available for general operating or investment purposes.